We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Merck Receives Complete Response Letter for Keytruda Breast Cancer Indication
Merck Receives Complete Response Letter for Keytruda Breast Cancer Indication
Merck has hit another snag as it seeks a new breast cancer indication for its blockbuster oncology drug Keytruda — a Complete Response Letter (CRL) from the FDA seeking more supporting evidence for its supplemental Biologics License Application (sBLA).